 | | |
|---|
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
| Dr Luke Hesson
Prince of Wales Clinical SchoolStatement of Interests:
Research within the Molecular and Cellular Oncology Laboratory aims to investigate the genetic and epigenetic basis of colon cancer.
More...
| |
| Dr Tzong-Tyng Hung
Prince of Wales Clinical SchoolStatement of Interests:
Secondary bone lesions (bone metastasis) is a major cause of mortality and morbidity in prostate cancer. The mechanisms of bone metastasis is still unclear. In order to study bone metastasis, we have developed murine models that are bone metastatic. Using various imaging and detection systems (microCT scans for small animals, Bioluminescence imaging, Fluorescent imaging and ultrasound) we are able to monitor development of bone metastatic lesions and pinpoint the site of bone tumours. Importantly, our models involve immune competent mice, which allows us to investigate the role of immune cells on the development of secondary bone tumours in prostate cancer and also evaluate potential therapies which include immunotherapies.
More...
| |
| Dr John Pimanda
Prince of Wales Clinical SchoolStatement of Interests:
Haematopoietic Stem Cells (HSCs) represent the best characterized adult multipotent stem cell population. Transcriptional regulation is a key mechanism controlling the formation and subsequent behaviour of HSCs. To investigate gene regulatory networks that operate during HSC specification, we use computational tools to predict regulatory elements of key haematopoietic transcription factor genes. We then filter these predictions using array based chromatin accessibility and transcription factor binding profiles. Transgenic mice are generated to test whether these predicted elements show tissue specific activity in the developing embryo. We also investigate mesenchymal stem/progenitor cell (MSCs)development to compare and contrast gene transcription between HSCs and MSCs. Knowledge of the normal transcriptional hierarchies of these cell types can be applied to better understand the dysregulation of these networks in the pathogenesis of cancer. To this end, we also study the biology of blood stem cell dyscrasias with a particular focus on the myelodysplastic and myeloproliferative syndromes.
More...
| |
| ![Show details for [<FONT SIZE=2 FACE="Verdana"><b>]Dr Carl A Power[</b><br>    <i>Prince of Wales Clinical Schoo](/icons/expand.gif) Dr Carl A Power
Prince of Wales Clinical SchoolStatement of Interests:
In the area of cancer biology in general and specifically prostate cancer biology. Research is focused on use of animal models to identify mechanisms of prostate cancer metastasis to bone, immune responses to prostate cancer and its bone metastases and preclinical assessment of treatments to prevent bone mets.
More...
| |
| Professor Pam Russell
Prince of Wales Clinical School - Department of MedicineStatement of Interests:
The Oncology Research Centre has been working since 1992 on preclinical studies of cancer, mostly prostate and bladder cancer, but also other cancers, including ovarian, colon and sarcoma. There are four main research areas: molecular studies of how cancers progress; gene therapy (suicide and immunological genes) for advanced prostate cancer, studies of the biology of and treatment for tumours that spread to the bone, and studies using targeted nanoparticles to improve cancer imaging. Approaches include the use of conditionally replicative adenoviruses with both transcriptional control and surface modulation of the virus to target cancer cells and deliver genes into tumours, animal models, including the growth of human tumours in the tibia of immunosuppressed mice or after intracardiac injection, that allows spontaneous spread to other organs, and microarray to identify genes of importance in the invasive/metastatic process. In addition, we are involved in the development of an animal imaging facility that is closely aligned to a specific pathogen free facility for rodents, so that preclinical studies can be appropriately performed in a longitudinal fashion, following through individual mice over time.
More...
| |
| Dr Yan Yu
Prince of Wales Clinical School - Department of SurgeryStatement of Interests:
Dr Yan Yu is currently a Principal Hospital Scientist of Prince of Wales Hospital and the Section Head of Orthopaedic Pathology & Molecular Biology of the Surgical & Orthopaedic Research Laboratories. She is also a conjoint senior lecturer of the Faculty of Medicine, University of New South Wales. She obtained a PhD degree for her work on allergy and immunology from the University of Bern in Switzerland in 1992. She is one of the pioneers in the establishment of the Surgical & Orthopaedic Research Laboratories. Her research specialties range from animal surgery to tissue pathology, cell biology, protein analysis and molecular biology. Her research interests includes skeletal responses to injuries and/or implantations; osteoporosis and osteoporotic bone defect healing; osteogenesis and tumourigenesis of human osteosarcoma cell lines; mechanisms of osteosarcoma local growth and distance metastasis and targeted therapies; tendon healing; amongst others.
More...
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |